{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hydroxyurea",
    "query": {
      "intervention": "Hydroxyurea"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 197,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hydroxyurea&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T00:23:53.938Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02788201",
      "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "75 approved agents",
          "type": "DRUG"
        },
        {
          "name": "COXEN",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2017-03-27",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788201"
    },
    {
      "nct_id": "NCT00519701",
      "title": "Hydroxyurea in Young Children With Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "18 Months to 5 Years"
      },
      "enrollment_count": 14,
      "start_date": "2002-04",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2007-08-23",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00519701"
    },
    {
      "nct_id": "NCT01461837",
      "title": "Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "CD34 selected T-cell depleted allogeneic SCT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 21,
      "start_date": "2012-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01461837"
    },
    {
      "nct_id": "NCT00001958",
      "title": "Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta Thalassemia",
        "Hemoglobinopathy"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "1999-12",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001958"
    },
    {
      "nct_id": "NCT00333840",
      "title": "Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "imatinib mesilate",
          "type": "DRUG"
        },
        {
          "name": "interferon-alpha (INF-a)",
          "type": "DRUG"
        },
        {
          "name": "cytarabine (ARA-C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1106,
      "start_date": "2000-06",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-10-14",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333840"
    },
    {
      "nct_id": "NCT01369160",
      "title": "Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Quality of Life measures",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "23 Years",
        "sex": "ALL",
        "summary": "3 Years to 23 Years"
      },
      "enrollment_count": 33,
      "start_date": "2005-05",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-05-28",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369160"
    },
    {
      "nct_id": "NCT00203905",
      "title": "A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil, Hydroxyurea-[FHX]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2004-01",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2014-01-17",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00203905"
    },
    {
      "nct_id": "NCT00122980",
      "title": "Stroke With Transfusions Changing to Hydroxyurea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemochromatosis",
        "Cerebrovascular Accident",
        "Anemia, Sickle Cell",
        "Hematologic Diseases"
      ],
      "interventions": [
        {
          "name": "Red Cell Transfusions",
          "type": "PROCEDURE"
        },
        {
          "name": "Iron Chelation",
          "type": "PROCEDURE"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Phlebotomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "5 Years to 18 Years"
      },
      "enrollment_count": 134,
      "start_date": "2006-10",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00122980"
    },
    {
      "nct_id": "NCT00002420",
      "title": "The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Emivirine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Delavirdine mesylate",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-08-14",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 1,
      "location_summary": "Beverly Hills, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002420"
    },
    {
      "nct_id": "NCT03825341",
      "title": "Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "9 Months to 18 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-06-10",
      "completion_date": "2022-01-20",
      "has_results": true,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-09-02T00:23:53.938Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03825341"
    }
  ]
}